Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deca-Durabolin for muscle weakness and weight loss in critically ill non-ventilated ICU patients
PACTR202408913510687Recruiting
- Sponsor
- no sponsor
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in critical illness neuromuscular disease (CINM) comparing Deca-Durabolin with Placebo (2 arms). Primary endpoint: Quadriceps femoris muscle thickness. Started May 2024; status: recruiting.
02
Drugs
nandrolone
03
Conditions
critical illness neuromuscular disease (CINM)
Beyond the preview
Go deeper on PACTR202408913510687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202408913510687.